Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest if you would like updates on the meeting or topic.
The IMPACCT Real World Evidence Summit West
Is your organization ready to lead the next era of evidence generation?
With CMS rolling out new guidance for real-world data studies and the FDA launching its Center for RWE Innovation, the message is clear: real-world evidence is no longer optional it's essential. As data becomes more accessible and advanced analytics unlock deeper insights, investment in RWE is accelerating at an unprecedented pace.
The West Coast is filled with forward-thinking pharma and biotech companies are harnessing AI, digital health, and real-world data to uncover unmet needs, demonstrate treatment value beyond the clinical trial setting, and influence decision-making across regulators, payers, providers, and patients.
Are you keeping up or leading the change?
Join the RWE leaders shaping this movement at the IMPACCT Real World Evidence Summit West and discover how to transform data into decisions across the entire product lifecycle.
What is best practice in selecting the right datasets and how can data quality be trusted? What are regulators and payers actually looking for as supporting evidence? How can integrated evidence generation plans be streamlined across functions?
Following the successful Boston and European meetings, the IMPACCT Real World Evidence Summit West is uniting RWE experts across Clinical Development, Value & Access, HEOR, and Commercial teams to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.
Example Agenda
• Uncover what constitutes ‘fit-for-purpose’ evidence from a payer and HTA body perspective.
• Enhance the predictive value of real-world studies through deeper biological context and mechanistic understanding.
• Balancing nuance and clarity while ensuring analytical complexity and audience accessibility is preserved.
• Takeaways from industry strategies to move from reactive fixes to proactive data governance and quality-by-design approaches.
